Andrew Nichols

Chief Scientific Officer at Astria Therapeutics

Andrew Nichols is currently the Chief Scientific Officer at Astria Therapeutics. Andrew has held this position since February 2014. Prior to this, they were with Merck as an Associate Vice President from July 2009 to February 2014. In this role, they were responsible for leading drug discovery efforts in cardiometabolic diseases through a combination of internal and external activities.

From April 2008 to July 2009, Nichols was with Zafgen, Inc. as their Vice President. In this role, they were responsible for leading and managing the pre-clinical biology activities in metabolic diseases (biology, pharmacology, DMPK, safety assessment) up to IND filing through a combination of in-house and external (CRO and collaborator) activities.

From November 2005 to April 2008, Nichols was with Alinea Pharmaceuticals as their Vice President. In this role, they were Alinea’s chief scientist with responsibility to oversee all discovery and development activities in metabolic diseases and to build and manage the processes required to transition compounds from discovery through pre-clinical development and early human clinical trials working with CROs and collaborators in a virtual company environment.

Before joining Alinea Pharmaceuticals, Nichols held the position of Senior Director to Vice President at Millennium Pharmaceuticals, Inc. from March 1999 to November 2005.

After completing their BSc in pharmacology at the University of Leeds, Andrew Nichols went on to earn their Ph.D. in the same field from the University of Cambridge.

Andrew Nichols works with Andrew A. Komjathy - Chief Commercial Officer, Noah Clauser - Chief Financial Officer, and Andrea Matthews - SVP, Corporate Affairs. Andrew Nichols reports to Jill C. Milne, Co-Founder & CEO.

Timeline

  • Chief Scientific Officer

    Current role

View in org chart